Alicia R. Folgueras
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Alicia R. Folgueras has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
- Carlos López-Otín
Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Paris, France; Facultad de Ciencias de la Vida y la Naturaleza, Universidad Nebrija, Madrid 28248, Spain
15 shared publications - Alejandro López-Soto
Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Instituto Universitario de Oncología del Principado de Asturias (IUOPA) Universidad de Oviedo Oviedo Spain
7 shared publications - Alberto M. Pendas
Molecular Mechanisms Program, Centro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer (CSIC-Universidad de Salamanca), Salamanca, Spain
6 shared publications Francisco Rodríguez
Departamento de Bioquímica y Biología Molecular, Facultad de Medicina Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Universidad de Oviedo Oviedo Spain
5 shared publications- Aurora Astudillo
Hospital Universitario Central de Asturias
4 shared publications - Sandra Freitas-Rodríguez
Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Universidad de Oviedo, Oviedo, Spain
4 shared publications
Latest Publications
- Open Access
- 9 August 2026
- Published by Wiley in Aging Cell
- Vol. 25 (8) , e70655
Targeting RANKL Prevents Bone Loss, Improves Muscle Function and Extends Lifespan in Progeroid Mice
Hutchinson‐Gilford progeria syndrome (HGPS) is a rare genetic disorder characterized by the early development of pathological features associated with aging, ultimately leading to premature death. HGPS primarily affects tissues of mesenchymal origin, as evidenced by the clinical manifestations characteristic of this premature aging disorder, including, but not limited to, osteoporosis, muscle wasting, lipodystrophy, and cardiovascular disease. In this study, we used preclinical mouse models and both genetic and translational approaches to investigate whether an antiresorptive strategy, based on RANKL targeting, ameliorated the bone loss phenotype of progeroid mice. Here we show that osteocyte‐derived RANKL deletion in the Zmpste24 −/− mouse model of HGPS reverted bone loss in both long bones and vertebrae. These mice also exhibited increased grip strength and improved endurance capacity. Furthermore, Zmpste24 −/− mice showed increased survival upon osteocyte‐specific RANKL deletion. Notably, the use of a translational approach based on the administration of a neutralizing antibody against RANKL also restored bone mass, reduced muscle fibrosis, and extended the lifespan of Zmpste24 −/− mice. Altogether, these findings support that targeting RANKL exerts a beneficial effect on both osseous and extra‐osseous phenotypes of HGPS, suggesting the potential of this therapeutic approach to explore in the treatment of this disease.
- 9 August 2026
- Published by Wiley in Aging Cell
- Vol. 25 (8) , e70655
Open AccessTargeting RANKL Prevents Bone Loss, Improves Muscle Function and Extends Lifespan in Progeroid Mice
Hutchinson‐Gilford progeria syndrome (HGPS) is a rare genetic disorder characterized by the early development of pathological features associated with aging, ultimately leading to premature death. HGPS primarily affects tissues of mesenchymal origin, as evidenced by the clinical manifestations characteristic of this premature aging disorder, including, but not limited to, osteoporosis, muscle wasting, lipodystrophy, and cardiovascular disease. In this study, we used preclinical mouse models and both genetic and translational approaches to investigate whether an antiresorptive strategy, based on RANKL targeting, ameliorated the bone loss phenotype of progeroid mice. Here we show that osteocyte‐derived RANKL deletion in the Zmpste24 −/− mouse model of HGPS reverted bone loss in both long bones and vertebrae. These mice also exhibited increased grip strength and improved endurance capacity. Furthermore, Zmpste24 −/− mice showed increased survival upon osteocyte‐specific RANKL deletion. Notably, the use of a translational approach based on the administration of a neutralizing antibody against RANKL also restored bone mass, reduced muscle fibrosis, and extended the lifespan of Zmpste24 −/− mice. Altogether, these findings support that targeting RANKL exerts a beneficial effect on both osseous and extra‐osseous phenotypes of HGPS, suggesting the potential of this therapeutic approach to explore in the treatment of this disease.
- 23 May 2025
- Published by Springer Nature
- Vol. 2930, 45-53
Magnetic Bead-Based Isolation of CD8+ T Cells from the Mouse Spleen
The immune system serves as a barrier limiting the initiation and progression of new tumors. Among its cellular components, CD8+ T cytotoxic cells are integral to the immune response against cancer. These cells can identify and combat tumor cells by releasing lytic granules, thereby driving the adaptive immune response. However, their function can be hindered by several factors such as immunosuppression in the tumor microenvironment, T cell exhaustion, and immunosenescence. Consequently, dissecting these mechanisms is essential to fully comprehend the immune response against cancer cells and can aid in tailoring future antitumor immunotherapies. In this chapter, we outline a straightforward method for isolating CD8+ T cells from the mouse spleen. These cells can then be further analyzed or utilized in in vitro functional studies, such as coculture with target tumor cells and assessing their cytotoxic activity and cytokine production profiling.
- 23 May 2025
- Published by Springer Nature
- Vol. 2930, 45-53
Magnetic Bead-Based Isolation of CD8+ T Cells from the Mouse Spleen
The immune system serves as a barrier limiting the initiation and progression of new tumors. Among its cellular components, CD8+ T cytotoxic cells are integral to the immune response against cancer. These cells can identify and combat tumor cells by releasing lytic granules, thereby driving the adaptive immune response. However, their function can be hindered by several factors such as immunosuppression in the tumor microenvironment, T cell exhaustion, and immunosenescence. Consequently, dissecting these mechanisms is essential to fully comprehend the immune response against cancer cells and can aid in tailoring future antitumor immunotherapies. In this chapter, we outline a straightforward method for isolating CD8+ T cells from the mouse spleen. These cells can then be further analyzed or utilized in in vitro functional studies, such as coculture with target tumor cells and assessing their cytotoxic activity and cytokine production profiling.
- Open Access
- 10 August 2023
- Published by Wiley in Aging Cell
- Vol. 22 (10) , e13952
The secretome atlas of two mouse models of progeria
Hutchinson‐Gilford progeria syndrome (HGPS) is a rare genetic disease caused by nuclear envelope alterations that lead to accelerated aging and premature death. Several studies have linked health and longevity to cell‐extrinsic mechanisms, highlighting the relevance of circulating factors in the aging process as well as in age‐related diseases. We performed a global plasma proteomic analysis in two preclinical progeroid models (LmnaG609G/G609G and Zmpste24−/− mice) using aptamer‐based proteomic technology. Pathways related to the extracellular matrix, growth factor response and calcium ion binding were among the most enriched in the proteomic signature of progeroid samples compared to controls. Despite the global downregulation trend found in the plasma proteome of progeroid mice, several proteins associated with cardiovascular disease, the main cause of death in HGPS, were upregulated. We also developed a chronological age predictor using plasma proteome data from a cohort of healthy mice (aged 1–30 months), that reported an age acceleration when applied to progeroid mice, indicating that these mice exhibit an “old” plasma proteomic signature. Furthermore, when compared to naturally‐aged mice, a great proportion of differentially expressed circulating proteins in progeroid mice were specific to premature aging, highlighting secretome‐associated differences between physiological and accelerated aging. This is the first large‐scale profiling of the plasma proteome in progeroid mice, which provides an extensive list of candidate circulating plasma proteins as potential biomarkers and/or therapeutic targets for further exploration and hypothesis generation in the context of both physiological and premature aging.
- 10 August 2023
- Published by Wiley in Aging Cell
- Vol. 22 (10) , e13952
Open AccessThe secretome atlas of two mouse models of progeria
Hutchinson‐Gilford progeria syndrome (HGPS) is a rare genetic disease caused by nuclear envelope alterations that lead to accelerated aging and premature death. Several studies have linked health and longevity to cell‐extrinsic mechanisms, highlighting the relevance of circulating factors in the aging process as well as in age‐related diseases. We performed a global plasma proteomic analysis in two preclinical progeroid models (LmnaG609G/G609G and Zmpste24−/− mice) using aptamer‐based proteomic technology. Pathways related to the extracellular matrix, growth factor response and calcium ion binding were among the most enriched in the proteomic signature of progeroid samples compared to controls. Despite the global downregulation trend found in the plasma proteome of progeroid mice, several proteins associated with cardiovascular disease, the main cause of death in HGPS, were upregulated. We also developed a chronological age predictor using plasma proteome data from a cohort of healthy mice (aged 1–30 months), that reported an age acceleration when applied to progeroid mice, indicating that these mice exhibit an “old” plasma proteomic signature. Furthermore, when compared to naturally‐aged mice, a great proportion of differentially expressed circulating proteins in progeroid mice were specific to premature aging, highlighting secretome‐associated differences between physiological and accelerated aging. This is the first large‐scale profiling of the plasma proteome in progeroid mice, which provides an extensive list of candidate circulating plasma proteins as potential biomarkers and/or therapeutic targets for further exploration and hypothesis generation in the context of both physiological and premature aging.
- 15 June 2018
- Published by Springer Nature in Molecular Neurobiology
- Vol. 56 (3) , 1578-1595
The Chemokine CCL4 (MIP-1β) Evokes Antinociceptive Effects in Mice: a Role for CD4+ Lymphocytes and Met-Enkephalin
In the present study, we characterize the antinociceptive effects produced by the chemokine CCL4 in mice. The intraplantar administration of very low doses of CCL4 (0.1–3 pg) produced bilateral antinociception assessed by the unilateral hot-plate test (UHP) without evoking chemotactic responses at the injection site. Moreover, the subcutaneous administration of CCL4 (3–100 pg/kg) also yielded bilateral antinociception in the UHP and the paw pressure test and reduced the number of spinal neurons that express Fos protein in response to noxious stimulation. The implication of peripheral CCR5 but not CCR1 in CCL4-evoked antinociception was deduced from the inhibition produced by systemic but not intrathecal, administration of the CCR5 antagonist DAPTA, and the inefficacy of the CCR1 antagonist J113863. Besides, the inhibition observed after subcutaneous but not intrathecal administration of naloxone demonstrated the involvement of peripheral opioids and the efficacy of naltrindole but not cyprodime or nor-binaltorphimine supported the participation of δ-opioid receptors. In accordance, plasma levels of met-enkephalin, but not β-endorphin, were augmented in response to CCL4. Likewise, CCL4-evoked antinociception was blocked by the administration of an anti-met-enk antibody. Leukocyte depletion experiments performed with cyclophosphamide, anti-Ly6G, or anti-CD3 antibodies indicated that the antinociceptive effect evoked by CCL4 depends on circulating T lymphocytes. Double immunofluorescence experiments showed a four times more frequent expression of met-enk in CD4+ than in CD8+ T lymphocytes. CCL4-induced antinociception almost disappeared upon CD4+, but not CD8+, lymphocyte depletion with selective antibodies, thus supporting that the release of met-enk from CD4+ lymphocytes underlies the opioid antinociceptive response evoked by CCL4.
- 15 June 2018
- Published by Springer Nature in Molecular Neurobiology
- Vol. 56 (3) , 1578-1595
The Chemokine CCL4 (MIP-1β) Evokes Antinociceptive Effects in Mice: a Role for CD4+ Lymphocytes and Met-Enkephalin
In the present study, we characterize the antinociceptive effects produced by the chemokine CCL4 in mice. The intraplantar administration of very low doses of CCL4 (0.1–3 pg) produced bilateral antinociception assessed by the unilateral hot-plate test (UHP) without evoking chemotactic responses at the injection site. Moreover, the subcutaneous administration of CCL4 (3–100 pg/kg) also yielded bilateral antinociception in the UHP and the paw pressure test and reduced the number of spinal neurons that express Fos protein in response to noxious stimulation. The implication of peripheral CCR5 but not CCR1 in CCL4-evoked antinociception was deduced from the inhibition produced by systemic but not intrathecal, administration of the CCR5 antagonist DAPTA, and the inefficacy of the CCR1 antagonist J113863. Besides, the inhibition observed after subcutaneous but not intrathecal administration of naloxone demonstrated the involvement of peripheral opioids and the efficacy of naltrindole but not cyprodime or nor-binaltorphimine supported the participation of δ-opioid receptors. In accordance, plasma levels of met-enkephalin, but not β-endorphin, were augmented in response to CCL4. Likewise, CCL4-evoked antinociception was blocked by the administration of an anti-met-enk antibody. Leukocyte depletion experiments performed with cyclophosphamide, anti-Ly6G, or anti-CD3 antibodies indicated that the antinociceptive effect evoked by CCL4 depends on circulating T lymphocytes. Double immunofluorescence experiments showed a four times more frequent expression of met-enk in CD4+ than in CD8+ T lymphocytes. CCL4-induced antinociception almost disappeared upon CD4+, but not CD8+, lymphocyte depletion with selective antibodies, thus supporting that the release of met-enk from CD4+ lymphocytes underlies the opioid antinociceptive response evoked by CCL4.
- Open Access
- 10 April 2018
- Published by Springer Nature in Nature Communications
- Vol. 9 (1) , 1-12
Matriptase-2 deficiency protects from obesity by modulating iron homeostasis
Alterations in iron status have frequently been associated with obesity and other metabolic disorders. The hormone hepcidin stands out as a key regulator in the maintenance of iron homeostasis by controlling the main iron exporter, ferroportin. Here we demonstrate that the deficiency in the hepcidin repressor matriptase-2 (Tmprss6) protects from high-fat diet-induced obesity. Tmprss6 −/− mice show a significant decrease in body fat, improved glucose tolerance and insulin sensitivity, and are protected against hepatic steatosis. Moreover, these mice exhibit a significant increase in fat lipolysis, consistent with their dramatic reduction in adiposity. Rescue experiments that block hepcidin up-regulation and restore iron levels in Tmprss6−/− mice via anti-hemojuvelin (HJV) therapy, revert the obesity-resistant phenotype of Tmprss6−/− mice. Overall, this study describes a role for matritpase-2 and hepcidin in obesity and highlights the relevance of iron regulation in the control of adipose tissue function.
- 10 April 2018
- Published by Springer Nature in Nature Communications
- Vol. 9 (1) , 1-12
Open AccessMatriptase-2 deficiency protects from obesity by modulating iron homeostasis
Alterations in iron status have frequently been associated with obesity and other metabolic disorders. The hormone hepcidin stands out as a key regulator in the maintenance of iron homeostasis by controlling the main iron exporter, ferroportin. Here we demonstrate that the deficiency in the hepcidin repressor matriptase-2 (Tmprss6) protects from high-fat diet-induced obesity. Tmprss6 −/− mice show a significant decrease in body fat, improved glucose tolerance and insulin sensitivity, and are protected against hepatic steatosis. Moreover, these mice exhibit a significant increase in fat lipolysis, consistent with their dramatic reduction in adiposity. Rescue experiments that block hepcidin up-regulation and restore iron levels in Tmprss6−/− mice via anti-hemojuvelin (HJV) therapy, revert the obesity-resistant phenotype of Tmprss6−/− mice. Overall, this study describes a role for matritpase-2 and hepcidin in obesity and highlights the relevance of iron regulation in the control of adipose tissue function.
- 10 January 2018
- Published by Springer Nature
- Vol. 1731, 235-245
Cancer Susceptibility Models in Protease-Deficient Mice
For decades, proteases have been associated with cancer progression due to the ability of some members of this large group of enzymes to degrade tumor cell surroundings, thereby facilitating cancer invasion and dissemination. However, the generation of mouse models deficient in proteases has revealed the existence of a great variety of functions among proteolytic enzymes in cancer biology, including important tumor-suppressive roles. Therefore, in this chapter, we describe methods to chemically induce different types of cancer (lung adenocarcinoma, hepatocellular carcinoma, oral and esophageal carcinoma, colorectal carcinoma, skin cancer, and fibrosarcoma) in genetically modified mouse models to efficiently evaluate the specific pro- or antitumoral function of proteases in cancer.
- 10 January 2018
- Published by Springer Nature
- Vol. 1731, 235-245
Cancer Susceptibility Models in Protease-Deficient Mice
For decades, proteases have been associated with cancer progression due to the ability of some members of this large group of enzymes to degrade tumor cell surroundings, thereby facilitating cancer invasion and dissemination. However, the generation of mouse models deficient in proteases has revealed the existence of a great variety of functions among proteolytic enzymes in cancer biology, including important tumor-suppressive roles. Therefore, in this chapter, we describe methods to chemically induce different types of cancer (lung adenocarcinoma, hepatocellular carcinoma, oral and esophageal carcinoma, colorectal carcinoma, skin cancer, and fibrosarcoma) in genetically modified mouse models to efficiently evaluate the specific pro- or antitumoral function of proteases in cancer.
- Top Cited Papers
- 1 November 2017
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
- Vol. 1864 (11) , 2015-2025
The role of matrix metalloproteinases in aging: Tissue remodeling and beyond
- 1 November 2017
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
- Vol. 1864 (11) , 2015-2025
Top Cited PapersThe role of matrix metalloproteinases in aging: Tissue remodeling and beyond
- 1 May 2017
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 62, 151-161
Hyperalgesic and hypoalgesic mechanisms evoked by the acute administration of CCL5 in mice
- 1 May 2017
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 62, 151-161
Hyperalgesic and hypoalgesic mechanisms evoked by the acute administration of CCL5 in mice
- 1 March 2017
- Published by Elsevier in Trends in Immunology
- Vol. 38 (3) , 151-153
NKG2D Signaling: The Immune Subversive Side of HDAC3
- 1 March 2017
- Published by Elsevier in Trends in Immunology
- Vol. 38 (3) , 151-153
NKG2D Signaling: The Immune Subversive Side of HDAC3
- 30 January 2017
- Published by Elsevier in Trends in Cancer
- Vol. 3 (3) , 161-163
IFN Signaling and ICB Resistance: Time is on Tumor’s Side
- 30 January 2017
- Published by Elsevier in Trends in Cancer
- Vol. 3 (3) , 161-163
IFN Signaling and ICB Resistance: Time is on Tumor’s Side